非酒精性脂肪性肝病患者血清Chemerin和颈动脉内膜中层厚度的相关性

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)患者血清Chemerin和颈动脉内膜中层厚度(CIMT)的相关性。方法回顾性纳入2019年1月1日至2020年5月1日于新乡医学院第一附属医院就诊的96例NAFLD患者和体检中心35例健康体检者, 其中NAFLD患者CIMT≥1.0 mm定义为ACIMT组, CIMT<1.0 mm定义为NCIMT组, 健康体检者定义为对照组。比较三组研究对象性别、年龄、BMI、吸烟史、合并糖尿病病史、高血压病史、收缩压、舒张压、FBG、TC、TG、HDL-c、LDL-c、HbA1c、FPG、FINS、HOMA-IR、ALT、AST、UA、Chemerin和CIMT的差异, 相关性分析采用Pearson分析, NAFLD患者IMT的危险因素采用Logistic回归分析, 血清Chemerin水平诊断NAFLD患者IMT≥1.0 mm的临床效能采用ROC曲线评估。结果 TG、LDL-c、FINS、HOMA-IR、ALT、AST、Chemerin在对照组、NCIMT组和ACIMT组中依次升高, 组组比较均存在显著差异(P<0.05);FPG、UA和CIMT在对照组和NCIMT组中相比较均无显著差异(P>0.05);与对照组和NCIMT组相比较, ACIMT组中FPG、UA和CIMT均显著升高(P<0.05)。NAFLD患者CIMT水平与TG、LDL-c、HOMA-IR、UA和Chemerin均呈现显著正相关性, 相关系数分别为0.322、0.474、0.354、0.365和0.489。Logistic回归分析显示, TG(OR=4.221)、HOMA-IR(OR=1.353)、LDL-c(OR=5.548)和Chemerin(OR=8.015)是NAFLD患者CIMT的危险因素。血清中Chemerin表达水平诊断NAFLD患者CIMT≥1.0 mm的曲线下面积为0.885(95% CI:0.813~0.942, P<0.000), 当截断值为265.29 ng/mL时, 诊断敏感度和特异度分别为 93.24%和95.25%。结论 Chemerin是NAFLD患者CIMT增厚的一项危险因素, 其可作为临床上检测NAFLD患者颈动脉粥样硬化的一项生物学标志物。

关键词: 非酒精性脂肪性肝病, 颈动脉内膜中层厚度, Chemerin, 标志物

Abstract: Objective To explore the association of serum Chemerin levels and carotid intima-media thickness in patients with Nonalcoholic fatty liver disease (NAFLD).Methods A total of 96 patients with NAFLD, 35 healthy individuals (control group) were enrolled in our hospital between January 1st 2019 and May 1st 2020. When CIMT≥1.0mm were defined as ACIMT group and others were defined as NCIMT group according to the carotid intima-media thickness (CIMT) of 96 patients with NAFLD. The differences of sex, age, BMI, smoking history, history of diabetes mellitus, history of hypertension, systolic blood pressure, diastolic blood pressure, FBG, TC, TG, HDL-c, LDL-c, HbA1c, FPG, Fins, HOMA-IR, ALT, AST, UA, Chemerin and CMIT were detected and compared among the three groups. Pearson analysis was used for correlation analysis. The risk factors of CIMT in patients with NAFLD were analyzed by logistic regression analysis. The clinical efficacy of serum Chemerin levels in the evaluating the CIMT≥1.0 mm, patients with NAFLD was analyzed by ROC curve. Results Serum levels of TG, LDL-c, FINS, ALT, AST, Chemerin and HOMA-IR in the control group, NCIMT group and ACIMT group increased gradually and there was significant difference between each group (P<0.05). There was no significant difference in serum FPG, UA levels and CIMT between the control group and NCIMT group (P>0.05). When compared with the control group and NCIMT group, serum FPG, UA levels and CIMT were significantly higher in ACIMT group (P<0.05). There was a significant positive correlation between CIMT levels and TG, LDL-C, HOMA-IR, UA and Chemerin in NAFLD patients. The correlation coefficients were 0.322, 0.474, 0.354, 0.365 and 0.489, respectively. Logistic regression analysis showed that TG (OR=4.221), HOMA-IR (OR=1.353), LDL-c (OR=5.548) and Chemerin (OR=8.015) were risk factors of CIMT in patients with NAFLD. The AUC of Chemerin in the diagnosis of CIMT≥1.0 mm in patients with NAFLD was 0.885 (95%CI: 0.813~0.942, P<0.000). When the cut-off value was 265.29 ng/mL, the sensitivity and specificity was 93.24% and 95.25%, respectively.Conclusion Chemerin is a risk factor of CIMT thickening and it can be used as a biomarker to detect carotid atherosclerosis in patients with NAFLD.

Key words: Nonalcoholic fatty liver disease, Carotid intima-media thickness, Chemerin;Biomarker

高海丽, 杨道坤, 梁海军, 王新伟, 王燕平, 陈宝鑫. 非酒精性脂肪性肝病患者血清Chemerin和颈动脉内膜中层厚度的相关性[J]. 肝脏, 2021, 26(4): 429-434.

GAO Hai-li, YANG Dao-kun, LIANG Hai-jun, WANG Xin-wei, WANG Yan-ping, CHEN Bao-xin. Association of serum Chemerin levels and carotid intima-media thickness in patients with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2021, 26(4): 429-434.

参考文献

[1] Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017, 23: 8263-8276.
[2] Lee JE, Lee YJ, Chung SY, et al. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men. PLoS One, 2018, 13: e0193191.
[3] Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44: 865-873.
[4] 王鹏, 修春红, 王岚峰. 颈动脉粥样硬化与心脑血管疾病的关系. 中国动脉粥样硬化杂志, 2014, 22: 1175-1178.
[5] Fu J, Deng HY, Hu ML, et al. Relationships between serum cystatin C, chemerin levels and subclinical atherosclerosis in type 2 diabetes mellitus patients. Zhonghua Yi Xue Za Zhi, 2019, 99: 307‐311.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版).中华肝脏病杂志, 2010, 18: 163-166.
[7] 中国医师协会超声医师分会. 血管超声检查指南. 中华超声影像学杂志, 2009, 18: 911-1012.
[8] Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis, 2018, 22:133-140.
[9] Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016, 65: 589-600.
[10] Oni E, Budoff MJ, Zeb I, et al. Nonalcoholic fatty liver disease is associated with arterial distensibility and carotid intima-media thickness: (from the multi-ethnic study of atherosclerosis). Am J Cardiol, 2019, 124: 534-538.
[11] Stojek M. The role of chemerin in human disease. Postepy Hig Med Dosw (Online), 2017, 71: 110-117.
[12] 吕骥, 闫丽丽, 贾红玉, 等. 血清chemerin水平与非酒精性脂肪性肝病的相关性. 中国肝脏病杂志(电子版), 2018, 10: 54-58.
[13] Krautbauer S, Wanninger J, Eisinger K, et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol, 2013, 95:199-205.
[14] Docke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol, 2013, 169: 547-557.
[15] Liu H, Xiong W, Luo Y, et al. Adipokine chemerin stimulates progression of atherosclerosis in ApoE-/- mice. Biomed Res Int, 2019, 2019: 7157865.
[16] Dimitriadis GK, Kaur J, Adya R, et al. Chemerin induces endothelial cell inflammation: activation of nuclear factor-kappa beta and monocyte-endothelial adhesion. Oncotarget, 2018, 9: 16678-16690 .
[17] 张艳丽. Chemerin与动脉粥样硬化稳定性的相关性研究. 吉林医学, 2016, 37: 2966-2968.
[18] Zhao D, Bi G, Feng J, et al. Association of serum chemerin levels with acute ischemic stroke and carotid artery atherosclerosis in a Chinese population. Med Sci Monit, 2015, 21:3121-3128.
[19] Lachine NA, Elnekiedy AA, Megallaa MH, et al. Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab, 2016, 7: 47-56.
[20] 王萍, 唐光才, 舒健, 等. 非酒精性脂肪肝肝/脾CT值与血脂的关系研究. 西南医科大学学报, 2018, 41: 67-70.
[21] Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev, 2019, 40: 1447-1467.
[22] 冯南山. 非糖尿病缺血性卒中患者胰岛素抵抗与动脉粥样硬化的相关性研究. 医学临床研究, 2017, 34: 136-138.